Pharma BD Deal Intelligence

Novartis AG / Zonsen PepLib Biotech Inc.

2026 · Licensing/Option · Complete

Zonsen PepLib Biotech and Novartis signed a worldwide exclusive license agreement for an undisclosed peptide-based asset in radioligand therapy. Novartis assumes responsibility for development and commercialization worldwide. Zonsen PepLib receives USD 50M upfront and is eligible for undisclosed development, regulatory and sales milestones plus tiered royalties on global net sales.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Novartis AG deals